<DOC>
	<DOCNO>NCT00039130</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Combining chemotherapy rituximab filgrastim may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine rituximab chemotherapy filgrastim treat patient Burkitt 's lymphoma Burkitt 's leukemia .</brief_summary>
	<brief_title>Rituximab , Chemotherapy , Filgrastim Treating Patients With Burkitt 's Lymphoma Burkitt 's Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate patient previously untreated Burkitt 's lymphoma Burkitt 's leukemia treat rituximab high-intensity chemotherapy filgrastim ( G-CSF ) support . - Determine progression-free overall survival patient treat regimen . - Determine feasibility toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord disease ( leukemia v lymphoma ) . - Course 1 : Patients receive cyclophosphamide IV 5-15 minute daily day 1-5 oral prednisone day 1-7 . Allopurinol PO give day 1-14 . - Courses 2 , 4 , 6 : Patients receive ifosfamide IV 1 hour daily day 1-5 ; vincristine IV 10 minute methotrexate IV 24 hour day 1 ; leucovorin calcium IV 15 minute every 6 hour day 2 ; cytarabine IV 2 hour day 4 5 etoposide IV 1 hour daily day 4 5 ; oral dexamethasone daily day 1-5 ; methotrexate cytarabine intrathecally ( IT ) day 1 . During course 2 , patient receive rituximab IV 1-4 hour day 8 , 10 , 12 . During course 4 6 , patient receive rituximab IV 1 hour day 8 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 7 continue blood count recover . - Courses 3 , 5 , 7 : Patients receive cyclophosphamide IV 5-15 minute daily day 1-5 ; vincristine IV 10 minute methotrexate IV 24 hour day 1 ; leucovorin calcium IV every 6 hour day 2 ; doxorubicin IV daily day 4 5 ; oral dexamethasone daily day 1-5 ; methotrexate cytarabine IT day 1 ; rituximab IV 1 hour day 8 . Patients also receive G-CSF course 2 , 4 , 6 . After course 3 , treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 100 patient ( 50 per stratum ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically , cytogenetically , immunophenotypically confirm Burkitt 's leukemia Burkitt 's Burkittlike lymphoma L3 morphology surface IgG expression Cytogenetic evidence ( 8 ; 14 ) , ( 8 ; 22 ) , ( 2 ; 8 ) Previously untreated disease except hydroxyurea leukocytosis CNS involvement allow Patients Burkitt 's leukemia Burkitt 's lymphoma bone marrow involvement must also enrol CALGB8461 Patients Burkitt 's leukemia must also enrol CALGB9665 PATIENT CHARACTERISTICS : Age : 16 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent interleukin11 Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except nondiseaserelated condition ( e.g. , insulin diabetes ) No concurrent steroid except adrenal failure Radiotherapy : No concurrent palliative radiotherapy except wholebrain irradiation document CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
</DOC>